Experience of remote cardiac care during the <scp>COVID</scp>‐19 pandemic: the <scp>V‐LAP</scp>™ device in advanced heart failure

D’Amario, Domenico; Restivo, Attilio; Canonico, Francesco; Rodolico, Daniele; Galli, Mattía; Burzotta, Francesco; Vergallo, Rocco; Trani, Carlo; Aspromonte, Nadia; Crea, Filippo

doi:10.1002/ejhf.1900

Cited by 18 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…described the successful implementation of a telemedicine service (using phone technology) for HF patients, which was provided throughout lockdown with 58% of patients accessing the service 73 . Remote cardiac care can detect underlying disease progression and prevent decompensation during this pandemic as demonstrated by colleagues using V‐LAP™ System in an NYHA class III patient 74 . Successful adoption of a telemedicine‐based strategy has been integrated into an HF clinic during COVID‐19 with a transition to telemedicine services from in‐person visits 49 .…”

Section: Transitioning To a Telehealth Frameworkmentioning

confidence: 99%

“…73 Remote cardiac care can detect underlying disease progression and prevent decompensation during this pandemic as demonstrated by colleagues using V-LAP ™ System in an NYHA class III patient. 74 Successful adoption of a telemedicine-based strategy has been integrated into an HF clinic during COVID-19 with a transition to telemedicine services from in-person visits. 49 However, the authors highlight the invaluable role of in-person services and assessments, which should be recommended to the patient if needed.…”

Section: Transitioning To a Telehealth Frameworkmentioning

confidence: 99%

See 1 more Smart Citation

Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2. The clinical presentation of this virus mainly manifests in the respiratory system but may also lead to severe complications in the cardiovascular system. The global burden of COVID-19 has led to an unprecedented need to gain further insight into patient outcomes, management, and clinical practice. This review aims to provide an overview of the current literature on heart failure (HF) hospitalizations, management, and care pathways for supporting patients during and beyond this pandemic. A literature review of five areas of interest was conducted and included: (i) HF hospitalization; (ii) recognizing the needs and supporting HF patients during COVID-19; (iii) supporting rehabilitation services; (iv) transitioning to a telehealth framework; and (v) the need for evidence. Patients with new-onset or existing HF are particularly vulnerable, but a significant reduction in HF hospital admissions has been reported. During these periods of uncertainty, the current care pathways for acute and elective cardiac patients have had to change with the relocation of HF services to protect the vulnerable and reduce transmission of COVID-19. Optimizing community HF services has the potential to reduce the pressures on secondary care during the recovery from this pandemic. Telemedicine and virtual health care are emerging technologies and overcome the risk of in-person exposure. Successful remote delivery of cardiac rehabilitation services has been reported during the pandemic. Delivery of a robust telehealth framework for HF patients will improve communication between clinician and patient. The reduction in HF admissions is a concern for the future and may result in unintended mortality. New-onset and current HF patients must understand their diagnosis and future prognosis and seek help and support using the appropriate platform when needed. Realigning HF services and the use of telemedicine and virtual health care has great potential but needs to be carefully understood to ensure engagement and approval in this population to overcome barriers and challenges.

show abstract

Section: Transitioning To a Telehealth Frameworkmentioning

confidence: 99%

Section: Transitioning To a Telehealth Frameworkmentioning

confidence: 99%

Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The V-LAP sensor records an atrial ECG and provides left atrial waveform morphology, potentially allowing other comorbidities such as valvular regurgitation and arrhythmias to be detected. This is currently being evaluated in the VECTOR-HF trial in Europe [ 68 ]. Another device not yet commercially approved is a different type of pulmonary artery pressure sensor called Cordella from Endotronix, Inc.…”

Section: Future Directionsmentioning

confidence: 99%

Wireless Hemodynamic Monitoring in Patients with Heart Failure

Lander

Aldweib

Abraham

2021

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review Wireless hemodynamic monitoring in heart failure patients allows for volume assessment without the need for physical exam. Data obtained from these devices is used to assist patient management and avoid heart failure hospitalizations. In this review, we outline the various devices, mechanisms they utilize, and effects on heart failure patients. Recent Findings New applications of these devices to specific populations may expand the pool of patients that may benefit. In the COVID-19 pandemic with a growing emphasis on virtual visits, remote monitoring can add vital ancillary data. Summary Wireless hemodynamic monitoring with a pulmonary artery pressure sensor is a highly effective and safe method to assess for worsening intracardiac pressures that may predict heart failure events, giving lead time that is valuable to keep patients optimized. Implantation of this device has been found to improve outcomes in heart failure patients regardless of preserved or reduced ejection fraction.

show abstract

“…Objavljene su preporuke za prevladavanje tih izazova. [48][49][50] spOL i zATAJivANJe sRcA Žene čine polovicu bolesnika s HF-om. U njih je registrirana snižena učestalost HF-a do dobi od 75 godina i veći udio HFpEF-a, što je vjerojatno povezano s većom prevalencijom pretilosti i šećerne bolesti.…”

Section: Zatajivanje Srca U Vrijeme Pandemije Covid-a 19unclassified

“…Recommendations to overcome these challenges have been released. [48][49][50] sex ANd HeART fAiLURe Women account for half of patients with HF with a lower incidence rate until the age of 75 years, a higher proportion of HFpEF, probably related to the higher prevalence of obesity and diabetes mellitus. 1 Women with HF present a greater symptom burden and poorer quality of life as compared with men.…”

Section: Heart Failure During the Covid-19 Pandemicmentioning

confidence: 99%

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Bueno¹,

Moura²,

Lancellotti³

et al. 2021

Cardiologia Croatica

View full text Add to dashboard Cite

Experience of remote cardiac care during the COVID‐19 pandemic: the V‐LAP™ device in advanced heart failure

Abstract: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as

Cited by 18 publications

References 3 publications

Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19

Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19

Wireless Hemodynamic Monitoring in Patients with Heart Failure

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Contact Info

Product

Resources

About